Navigation Links
Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
Date:7/10/2008

ntibody with enhanced antibody effector function that targets CD70, a member of the TNF family that is highly expressed on multiple cancers, including renal cell carcinoma, lymphoma and glioblastoma. CD70 expression on activated lymphocytes may also be implicated in autoimmune diseases. Data from the ongoing Phase 1 trial in clear cell renal carcinoma is expected in 2009. Additional opportunities include the expected initiation of a Phase 1 trial of MDX-1411 in lymphomas in 2008, as well as an anti-CD70 antibody-drug conjugate program.

-- MDX-1203 targets the CD70 molecule expressed on multiple cancers and is expected to be the first Medarex antibody-drug conjugate candidate to enter clinical development in 2008/early 2009.

"We are making great strides in developing potentially important therapeutics to address a wide range of cancer and inflammatory diseases," Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We continue to progress towards proof-of-concept for multiple programs and look forward to advancing our most promising candidates towards market approval."

Research and Development

Medarex has enhanced its core UltiMAb(R) antibody platform with a suite of technologies that optimize or enhance the therapeutic activity of antibodies. One important technology expansion is the company's proprietary antibody-drug conjugate (ADC) platform. Medarex believes that its ADC technology overcomes many of the key development challenges of drug conjugates, including issues of linker stability, potency and multi-drug resistance while maintaining a wide therapeutic window with minimal toxicity. Coupled with cutting-edge antibody technologies, Medarex's sophisticated drug development infrastructure and decision-making processes engage expertise in the areas of science, clinical development and market research to maximize efficiency, increase productivity, augment the quality of our antibody drug development eff
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
8. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
9. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
(Date:7/31/2014)... Lazarus Effect, a medical device company focused ... removal of blood clots, announced the closing of a ... EU commercialization of several approved Lazarus Effect devices, as ... Lazarus Cover™ in the United States ... the value of our novel, platform technology as well ...
(Date:7/31/2014)... , July 31, 2014 For its innovative ... California , Art,s-Way Scientific has earned a Modular ... With competition in over 30 categories, MBI,s contest is ... members, which include building manufacturers, dealers, and product and ... excellent example the capability of our team," said ...
Breaking Medicine Technology:Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Lazarus Effect Closes $5 Million Financing 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... , SAN MATEO, Calif., Oct. 1 Corthera Inc. ... (FDA) has granted Fast Track designation to relaxin, the ... failure (AHF). The Fast Track program facilitates the development ... treat serious or life-threatening conditions and that demonstrate the ...
... Oct. 1 Health Strategies Group, a leading ... industries, has just launched Oncology Performance Edge, a new ... in the oncology field improve brand performance by understanding ... oncology market is significantly different from others, with unique ...
Cached Medicine Technology:Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 2Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 3Health Strategies Group Introduces Oncology Performance Edge 2Health Strategies Group Introduces Oncology Performance Edge 3
(Date:7/31/2014)... United Theological Seminary is pleased to welcome two ... Peter J. Bellini. Both began their teaching duties on ... Director of Non-Degree Programs, Mark Abbott, who begins his ... Assistant Professor of New Testament, received a Ph.D. from ... Temple Judaism, and Greek courses. His research interests are ...
(Date:7/31/2014)... July 31, 2014 Cosmetic Town is ... Plastic Surgeons to consumers considering cosmetic treatments. The ... peers whose goal is to educate prospective patients on ... selected through a validated referral system that helps patients ... best in their respective fields. , Cosmetic Town ...
(Date:7/31/2014)... The VitaSleep FDA cleared anti-snoring ... provide an easier breathing capacity by slightly adjusting the ... people can breathe easier and helps reduce or even ... that it can meet the needs of each individual ... shared by actual customer reviews. Johathan R. from ...
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... (LMS) which continues to help healthcare agencies to ... help companies and agencies meet their accreditation ... with competency based training. , Healthcare administrators ... a few clicks of the mouse. Courses can ...
(Date:7/31/2014)... Andrie, Inc. V. Dept. of Treasury, Mich. S. Ct., ... made the determination that a purchaser of tangible goods in ... unable to prove during an audit that sales tax ... of Appeals decision on whether a purchaser bears the burden ... from Michigan sellers. The Court states “in order to be ...
Breaking Medicine News(10 mins):Health News:Growing Seminary Welcomes New Faculty 2Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3
... Dr. Roberto Giraldo, an American physician who addressed ... malnutrition was one of the key factors that ... His website (www.robertogiraldo.com) says, "Aids is neither an ... a toxic-nutritional syndrome caused by the alarming worldwide ...
... as the time period immediately prior to menopause beginning ... year after the last menstrual periods, is a time ... a history of mood// disorders. Earlier studies have shown ... age (considered early) were two to three times more ...
... 61 previous studies of blood pressure and cardiovascular disease, which ... regardless of age and even if readings are in the ... reducing risk of strokes and heart attacks. ,The study ... that out of the 120,000 who died, 56,000 suffered fatal ...
... cessation has often been connected to gaining excess weight. ... gain could be related to the hormone leptin, which ... on assumptions that leptin levels were high during smoking ... smoking, the leptin levels plummet leading to weight gain. ...
... A supplemental new drug application (sNDA) for Valtrex (valacyclovir ... and Drug Administration (FDA) for the treatment of cold ... which also added that this new application for Valtrex// ... to shorten the duration of a cold sore outbreak. ...
... the most common reason which results in fatal complications ... potentially dangerous bug which causes this type of ... found naturally in the environment and survives drying and ... periods. This bacterium which is not harmful to healthy ...
Cached Medicine News:Health News:Depressed women show signs of earlier onset of Perimenopause 2Health News:Machines take over the battle against hospital bugs 2
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: